About Us  |  Contact Us  |  Español
Butler Hospital
butler_leftnavImage_logo
Butler Hospital
 
Genentech Crenezumab Research Study for Alzheimer's Disease
Genentech Crenezumab Research Study for Alzheimer's Disease

Alzheimer's Research Studies

What is the Genentech Crenezumab Study for Alzheimer's Disease?
This is a Phase II multicenter study evaluating the long-term safety and tolerability of the drug crenezumab in patients with mild-to-moderate Alzheimer's disease. 

What is the purpose of the Genentech Crenezumab Study?
To test long-term safety extension of Phase II Studies ABE4869g and ABE4955g in patients with mild to moderate Alzheimer's Disease.

Eligibility
Patients who participated in and completed the ABE486g or ABE 4955g Phase I clinical trial are eligible to participate.    

If you are interested in learning more about the Crenezumab study, please call (401) 455-6403 or send an e-mail to: memory@butler.org.

For information on other current research studies at Butler Hospital please click here.

Butler Hospital
© 2011 Site Index | Disclaimer | Legal Notices